[
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best cheap stocks under $50 to buy now. In a report released on July 13, Terence Flynn from Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb Company (NYSE:BMY), setting a price target of $34.00. The analyst based the rating on the company’s current market standing and future […]",
    "url": "https://finnhub.io/api/news?id=0050ff707bc85cfe4e07821a1fc8dfe5eb0f06a28c4e4cd249be1f68e6c38655",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752864423,
      "headline": "Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT",
      "id": 136012025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best cheap stocks under $50 to buy now. In a report released on July 13, Terence Flynn from Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb Company (NYSE:BMY), setting a price target of $34.00. The analyst based the rating on the company’s current market standing and future […]",
      "url": "https://finnhub.io/api/news?id=0050ff707bc85cfe4e07821a1fc8dfe5eb0f06a28c4e4cd249be1f68e6c38655"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program",
    "summary": "Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer, Inc. (NYSE:PFE) have announced a direct-to-patient program for Eliquis (apixaban), their top-selling blood thinner, in a move aimed at improving access for uninsured and underinsured patients. Starting September 8, 2025, eligible individuals will be able to […]",
    "url": "https://finnhub.io/api/news?id=18641e237c69da19d67780d5ef0783fd4cfce00d93cd89387f3bc600cd9cf95f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752864358,
      "headline": "Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program",
      "id": 136011993,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer, Inc. (NYSE:PFE) have announced a direct-to-patient program for Eliquis (apixaban), their top-selling blood thinner, in a move aimed at improving access for uninsured and underinsured patients. Starting September 8, 2025, eligible individuals will be able to […]",
      "url": "https://finnhub.io/api/news?id=18641e237c69da19d67780d5ef0783fd4cfce00d93cd89387f3bc600cd9cf95f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial",
    "summary": "Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions. The study did not meet its primary endpoint of RBC transfusion independence during any consecutive 12-week period, starting within the first 24 weeks of treatment, compared to placebo (p=0.0674).",
    "url": "https://finnhub.io/api/news?id=7c3ffe175d5bb70a64db9cc8c48e3420e1973fc25da6e022c9c0004df442b68e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752861253,
      "headline": "Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial",
      "id": 136011994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions. The study did not meet its primary endpoint of RBC transfusion independence during any consecutive 12-week period, starting within the first 24 weeks of treatment, compared to placebo (p=0.0674).",
      "url": "https://finnhub.io/api/news?id=7c3ffe175d5bb70a64db9cc8c48e3420e1973fc25da6e022c9c0004df442b68e"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=545c49964eef9b63f88649d5b4d9dd6dfe1ebb3fdaf0cb48a95e2b1805ce14eb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752856740,
      "headline": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
      "id": 136049841,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=545c49964eef9b63f88649d5b4d9dd6dfe1ebb3fdaf0cb48a95e2b1805ce14eb"
    }
  },
  {
    "ts": null,
    "headline": "July's 5 Dividend Growth Stocks With Yields Up To 7.96%",
    "summary": "July's 5 Dividend Growth Stocks With Yields Up To 7.96%",
    "url": "https://finnhub.io/api/news?id=2264f0b1d781b24dc3e87e7e123c18cc73e712a60f4b74c0d99455fa24e51e6a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752849968,
      "headline": "July's 5 Dividend Growth Stocks With Yields Up To 7.96%",
      "id": 136008446,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2264f0b1d781b24dc3e87e7e123c18cc73e712a60f4b74c0d99455fa24e51e6a"
    }
  },
  {
    "ts": null,
    "headline": "With 82% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing",
    "summary": "Key Insights Institutions' substantial holdings in Bristol-Myers Squibb implies that they have significant influence...",
    "url": "https://finnhub.io/api/news?id=cb4ea1997907dbd0d826d2a55a67950f4ac8b59f081ea0a9851dd32f8fe9f37e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752847220,
      "headline": "With 82% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing",
      "id": 136005865,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Key Insights Institutions' substantial holdings in Bristol-Myers Squibb implies that they have significant influence...",
      "url": "https://finnhub.io/api/news?id=cb4ea1997907dbd0d826d2a55a67950f4ac8b59f081ea0a9851dd32f8fe9f37e"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=8a9e423f8137b6052faf6b49cf1d5da87d7a9d6e9400804fdca033b91b295613",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752843602,
      "headline": "Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 136005866,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=8a9e423f8137b6052faf6b49cf1d5da87d7a9d6e9400804fdca033b91b295613"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia",
    "summary": "PRINCETON, N.J., July 18, 2025--BMS Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl in Adult Patients with Myelofibrosis-Associated Anemia",
    "url": "https://finnhub.io/api/news?id=68e91363f1d1c777147ef445dbf9f11e4e1f613502f4a0984f7e97bfe33f07b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752836340,
      "headline": "Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia",
      "id": 136005867,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., July 18, 2025--BMS Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl in Adult Patients with Myelofibrosis-Associated Anemia",
      "url": "https://finnhub.io/api/news?id=68e91363f1d1c777147ef445dbf9f11e4e1f613502f4a0984f7e97bfe33f07b3"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Posts Mixed Reblozyl Results in Myelofibrosis-Associated Anemia",
    "summary": "Bristol Myers Posts Mixed Reblozyl Results in Myelofibrosis-Associated Anemia",
    "url": "https://finnhub.io/api/news?id=341c518e24b26b40a80c7f2221eccd46d98d3ad96debd333f055529e4bd14b58",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752823740,
      "headline": "Bristol Myers Posts Mixed Reblozyl Results in Myelofibrosis-Associated Anemia",
      "id": 136049842,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Posts Mixed Reblozyl Results in Myelofibrosis-Associated Anemia",
      "url": "https://finnhub.io/api/news?id=341c518e24b26b40a80c7f2221eccd46d98d3ad96debd333f055529e4bd14b58"
    }
  },
  {
    "ts": null,
    "headline": "The Davenport Insider Buying Fund Q2 2025 Commentary",
    "summary": "Insider buying fuels Davenportâs contrarian bets in semis, housing, and LNG. See what signals fund managers trust when markets move against the grain.",
    "url": "https://finnhub.io/api/news?id=ca3d15c8d36faacca7f0f921829ec74383fca064ac9254718d546c4727f4a581",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752820800,
      "headline": "The Davenport Insider Buying Fund Q2 2025 Commentary",
      "id": 136000884,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2152882467/image_2152882467.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Insider buying fuels Davenportâs contrarian bets in semis, housing, and LNG. See what signals fund managers trust when markets move against the grain.",
      "url": "https://finnhub.io/api/news?id=ca3d15c8d36faacca7f0f921829ec74383fca064ac9254718d546c4727f4a581"
    }
  },
  {
    "ts": null,
    "headline": "The Davenport Balanced Fund Q2 2025 Commentary",
    "summary": "Davenport blends dividend discipline, bond yield upside, and contrarian equity picks in DBALX. See how balanced investing still finds value in 2025.",
    "url": "https://finnhub.io/api/news?id=4bdb422e2c4856f5d9f3007eff0a2fbd75d7735fa999ca6fde264ed6f71dd73f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752820500,
      "headline": "The Davenport Balanced Fund Q2 2025 Commentary",
      "id": 136000852,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2010464790/image_2010464790.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Davenport blends dividend discipline, bond yield upside, and contrarian equity picks in DBALX. See how balanced investing still finds value in 2025.",
      "url": "https://finnhub.io/api/news?id=4bdb422e2c4856f5d9f3007eff0a2fbd75d7735fa999ca6fde264ed6f71dd73f"
    }
  },
  {
    "ts": null,
    "headline": "The Davenport Value & Income Fund Q2 2025 Commentary",
    "summary": "The Davenport Value & Income Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=8fe250ebddd0c5cd485b556d16dd47deb781d90003a77552d4b3581b3cadd026",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752819300,
      "headline": "The Davenport Value & Income Fund Q2 2025 Commentary",
      "id": 136000824,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8fe250ebddd0c5cd485b556d16dd47deb781d90003a77552d4b3581b3cadd026"
    }
  }
]